Capricor Therapeutics is expected to release data from the phase 3 HOPE-3 trial in Q3'25, thus presenting a potential path ...

Dyne Therapeutics, Inc. (NASDAQ:DYN) is one of the 13 Best Healthcare Stocks to Buy Under $10. In a report released on July 7 ...

US biotech Capricor Therapeutics today revealed receipt of a Complete Response Letter (CRL) from the US Food and Drug ...

The company said it was optimistic that the issues identified by the Food and Drug Administration could be resolved with new data.

They said he wouldn’t make it this far. He’s proving them wrong -- one push at a time.” At just 16, Nathan Espina is defying ...

The U.S. Food and Drug Administration has declined to approve Capricor Therapeutics' cell therapy for a heart condition, the ...

Over 70 million Indians live with rare diseases, facing challenges like delayed diagnosis, high treatment costs, and limited ...

Capricor Therapeutics Inc. received a complete response letter (CRL) from the U.S. FDA on the BLA for deramiocel to treat cardiomyopathy in Duchenne muscular dystrophy patients. The company’s CEO said ...

Solid Biosciences' DMD gene therapy shows promise with SGT-003 and strong cash backing through 2027. Click here to read an ...

SAN DIEGO, CA, USA I July 11, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...